Clinical trials: Epilepsy; Seizure
Partial Epilepsy
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
- Trial name
- NCT04903314
- Testing
- Xcopri
- Where
- 13 sites in United States, Hungary and 1 more
- Volunteers
- 26 people
- Sponsor
- SK Life Science, Inc.
Generalized Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
- Trial name
- SHINE (NCT06425159)
- Testing
- BHV-7000
- Where
- 109 sites in United States, Australia and 12 more
- Volunteers
- 27 people
- Sponsor
- Biohaven Therapeutics Ltd.
Focal Onset Seizures
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal…
- Trial name
- NCT06377930
- Testing
- RAP-219
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapport Therapeutics Inc.
Focal Epilepsy, Epilepsy
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in…
- Conditions
- Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
- Trial name
- NCT07219407
- Testing
- RAP-219
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapport Therapeutics Inc.
Drug Resistant Epilepsy, Focal Seizure
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007
This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007.
- Trial name
- NCT06899230
- Testing
- iQ-007
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- iQure Australia Pty Ltd
Seizures
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
- Trial name
- NCT04686786
- Testing
- CVL-865
- Where
- 56 sites in United States, Australia and 5 more
- Volunteers
- 105 people
- Sponsor
- AbbVie
Dravet Syndrome
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
WAYFINDER is a Phase 1/2 study in Australia to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to <84 months. The study follows an open-label, dose-escalation design.
- Trial name
- NCT06112275
- Testing
- ETX101
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- Encoded Therapeutics
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
This study will be conducted to evaluate the safety, pharmacokinetics (PK), and efficacy of adjunctive GWP42003-P in participants < 2 years of age with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), or Dravet…
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Trial name
- NCT04485104
- Testing
- GWP42003-P
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Absence Epilepsy, Childhood, Absence Seizures
Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings
This study is being done to find out if a smartphone app can identify absence seizures. Children who have a history of absence seizures, as well as children without any seizure history, will be testing out the app.
- Conditions
- Absence Epilepsy, Childhood, Absence Seizures, Absence Epilepsy, Epilepsy in Children
- Trial name
- DASHER (NCT06093490)
- Testing
- Eysz Hyperventilation Recorder
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Eysz, Inc.
Childhood Absence Epilepsy, Absence Seizures
Assessing Comorbidities in Epilepsy Using Eye Movement Recordings
This study wants to make it easier to find kids with a type of epilepsy called childhood absence epilepsy (CAE) who might have problems with ongoing seizures and thinking.
- Conditions
- Childhood Absence Epilepsy, Absence Seizures, Epilepsy Comorbidities
- Trial name
- ACER (NCT06310772)
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eysz, Inc.
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization…
- Trial name
- NCT03083665
- Testing
- Brivaracetam
- Where
- 94 sites in China, Japan and 5 more
- Volunteers
- 449 people
- Sponsor
- UCB Biopharma SRL
Epilepsies, Myoclonic
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
- Trial name
- MOMENTUM 1 (NCT04572243)
- Testing
- Lorcaserin
- Where
- 30 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Eisai Inc.
Electroencephalographic Neonatal Seizures, Epilepsy
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
The purpose of the study is to evaluate the efficacy of lacosamide (LCM) versus an Active Comparator chosen based on standard of care (StOC) in severe and nonsevere seizure burden (defined as total minutes of…
- Trial name
- LENS (NCT04519645)
- Testing
- Lacosamide intravenous, Lacosamide oral, Active Comparator
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- UCB Biopharma SRL
Epilepsy With Uncontrolled Focal-onset Seizures
REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures.
- Trial name
- NCT06922175
- Where
- 10 sites in Germany, Netherlands and 3 more
- Volunteers
- 200 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Focal Epilepsy With and Without Secondary Generalization
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response…
- Trial name
- NCT06716801
- Testing
- Cenobamate
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Epilepsy
Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study
The purpose of this study is to describe the effectiveness of the adjunctive ASM treatment on the clinical response, safety profile and quality of life of patients affected by focal onset seizures in a real-world setting.
- Trial name
- NCT05867160
- Testing
- ASM as adjunctive therapy
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Epilepsy, Seizures
EpiCare@Home Validation Study for Focal Onset Seizures
The goal of this clinical trial is to validate a wearable seizure monitoring device, EpiCare@Home, as an objective seizure monitoring tool for people with focal onset epileptic seizures.
- Conditions
- Epilepsy, Seizures, Seizures, Focal, Seizure, Refractory
- Trial name
- NCT05738226
- Testing
- EpiCare@Home, wearable multimodal seizure monitoring system
- Where
- United States
- Sponsor
- Byteflies
Epilepsy, Focal-Onset Seizure
Cenobamate in Adults With Focal-Onset Seizures
The BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its…
- Conditions
- Epilepsy, Focal-Onset Seizure, Neurological Disorder
- Trial name
- BLESS (NCT05859854)
- Where
- 10 sites in Italy
- Volunteers
- 936 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.
- Trial name
- NCT03250377
- Testing
- Brivaracetam
- Where
- 59 sites in China, Japan
- Volunteers
- 207 people
- Sponsor
- UCB Biopharma SRL
Dravet Syndrome
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome.
- Trial name
- NCT02823145
- Testing
- ZX008 (Fenfluramine Hydrochloride)
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 375 people
- Sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.